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Abstract
Background
Potentially modifiable risk factors including obesity, diabetes, hypertension, and smoking
are associated with Alzheimer disease (AD) and represent promising targets for interven-
tion. However, the causality of these associations is unclear. We sought to assess the caus-
al nature of these associations using Mendelian randomization (MR).
Methods and Findings
We used SNPs associated with each risk factor as instrumental variables in MR analyses.
We considered type 2 diabetes (T2D, NSNPs = 49), fasting glucose (NSNPs = 36), insulin re-
sistance (NSNPs = 10), body mass index (BMI, NSNPs = 32), total cholesterol (NSNPs = 73),
HDL-cholesterol (NSNPs = 71), LDL-cholesterol (NSNPs = 57), triglycerides (NSNPs = 39), sys-
tolic blood pressure (SBP, NSNPs = 24), smoking initiation (NSNPs = 1), smoking quantity
(NSNPs = 3), university completion (NSNPs = 2), and years of education (NSNPs = 1). We cal-
culated MR estimates of associations between each exposure and AD risk using an in-
verse-variance weighted approach, with summary statistics of SNP–AD associations from
the International Genomics of Alzheimer’s Project, comprising a total of 17,008 individuals
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Data Availability Statement: All association data
with Alzheimer's disease for each individual SNP is
available from http://www.pasteur-lille.fr/en/recherche/
u744/igap/igap_download.php. Individual-level data
can be sought by request to the GERAD consortium
(http://gtr.rcuk.ac.uk/project/B6C58A7C-3C3E-41CB-
AF10-16DB59962C9E). To promote collaboration and
wide use of data in order to further Alzheimer’s
Disease research, qualified investigators can submit
proposals to conduct analyses using results from the
Genetic and Environmental Risk in Alzheimer’s
Disease (GERAD) analysis or, in collaboration with
with AD and 37,154 cognitively normal elderly controls. We found that genetically predicted
higher SBP was associated with lower AD risk (odds ratio [OR] per standard deviation [15.4
mm Hg] of SBP [95% CI]: 0.75 [0.62–0.91]; p = 3.4 × 10−3). Genetically predicted higher
SBP was also associated with a higher probability of taking antihypertensive medication (p
= 6.7 × 10−8). Genetically predicted smoking quantity was associated with lower AD risk
(OR per ten cigarettes per day [95% CI]: 0.67 [0.51–0.89]; p = 6.5 × 10−3), although we were
unable to stratify by smoking history; genetically predicted smoking initiation was not asso-
ciated with AD risk (OR = 0.70 [0.37, 1.33]; p = 0.28). We saw no evidence of causal associ-
ations between glycemic traits, T2D, BMI, or educational attainment and risk of AD (all p >
0.1). Potential limitations of this study include the small proportion of intermediate trait vari-
ance explained by genetic variants and other implicit limitations of MR analyses.
Conclusions
Inherited lifetime exposure to higher SBP is associated with lower AD risk. These findings
suggest that higher blood pressure—or some environmental exposure associated with
higher blood pressure, such as use of antihypertensive medications—may reduce AD risk.
Introduction
Alzheimer disease (AD) prevalence is rising [1], further increasing the social and economic
burden of this disease [2]. Epidemiological studies have aimed to identify potentially modifi-
able risk factors that could be targeted in preventive measures to reduce the incidence of AD.
These include type 2 diabetes (T2D) and glycemic traits [3,4], hypertension [5], obesity [6],
dyslipidemia [7], smoking [8], physical inactivity [5], depression [9], and low educational at-
tainment [5]. It has been reported that approximately one-third of AD cases worldwide may be
attributable to these risk factors [9]. However, this suggestion is predicated on these risk factors
having causal effects on AD risk, which is currently uncertain [9]. Given the difficulties in im-
plementing large-scale randomized trials of risk factor modification, alternative approaches are
required to investigate the causality of associations and to prioritize the targets for which inter-
ventions may be most fruitful [10].
One method for estimating the causal effects of risk factors with known genetic determi-
nants is Mendelian randomization (MR) [11]. The MR approach exploits the fact that geno-
types are randomly assorted at meiosis, and are thus independent of conventional confounding
factors and the disease process. Therefore, genetic variants associated with intermediate traits
can be used to provide an unconfounded estimate of the causal association between the inter-
mediate trait and disease outcome, unaffected by reverse causality. This is akin to a “genetically
randomized trial.” For example, if body mass index (BMI) is causally associated with AD, ge-
netic variants causing higher BMI should also be associated with higher risk of AD. However, if
an observed BMI—AD association is not causal but is due to confounding or reverse causation,
genetic variants causing higher BMI would not result in higher risk of AD. Here, we sought to
estimate the causal effects of potentially modifiable risk factors on risk of AD using MR to in-
form the etiology of AD and the extent to which AD may be preventable by interventions tar-
geting potentially modifiable risk factors.
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GERAD, to conduct analyses using data from
GERAD members. The PI and other key personnel
must be qualified investigators with appropriate
experience and have the support of at least one
GERAD collaborator. Proposals can be submitted at
any time and will be provided to all GERAD
members, who will be asked to review and feedback
to the GERAD coordinator (Julie Williams) within 2
weeks. Where objections or additional information is
sought the proposal may be discussed on the next
GERAD conference call. Further revision or
clarification may be requested at this time. After all
questions are addressed, the GERAD consortium will
provide any objections to the coordinator (Julie
Williams). All objections will be taken into account
and acted on appropriately. Individual members can
opt-out of projects. Proposals should not overlap with
analyses that are being performed within GERAD,
and should be new and novel research ideas. In
order to access GERAD data, the receiving Institution
is required to enter into a data sharing agreement
with Cardiff University which binds them to
appropriate use and acknowledgement of the data
they receive. Only parties involved in this agreement
can access GERAD data for the purpose specified in
the proposal.
Funding: This study was supported by the Innovative
Medicines Initiative Joint Undertaking under EMIF
grant agreement n° 115372 (contributions from the
European Union's Seventh Framework Programme
(FP7/2007-2013) and EFPIA companies). The work
was further supported by the National Institute for
Health Research (NIHR) Mental Health Biomedical
Research Centre and Dementia Unit at South London
and Maudsley NHS Foundation Trust and [Institute of
Psychiatry] King’s College London. SDØ is supported
by a grant from the Lundbeck Foundation. PP is an
Alzheimer’s Society Post-Doctoral Fellow. NJW is an
NIHR Senior Investigator. Funding for the EPIC-
InterAct project was provided by the EU FP6
programme (grant number
LSHM_CT_2006_037197). ADGC funding: The
National Institutes of Health, National Institute on
Aging (NIH-NIA) supported this work through the
following grants: ADGC, U01 AG032984, RC2
AG036528; NACC, U01 AG016976; NCRAD, U24
AG021886; NIA LOAD, U24 AG026395, U24
AG026390; Banner Sun Health Research Institute
P30 AG019610; Boston University, P30 AG013846,
U01 AG10483, R01 CA129769, R01 MH080295, R01
AG017173, R01 AG025259, R01AG33193; Columbia
University, P50 AG008702, R37 AG015473; Duke
University, P30 AG028377, AG05128; Emory
University, AG025688; Group Health Research
Institute, U01 AG06781, U01 HG004610, U01
HG006375; Indiana University, P30 AG10133; Johns
Hopkins University, P50 AG005146, R01 AG020688;
Methods
Study Design
We performed MR analyses using single nucleotide polymorphisms (SNPs) with known associ-
ations with potentially modifiable AD risk factors. We used summary statistics from the Inter-
national Genomics of Alzheimer’s Project (IGAP) [12], the largest genome-wide meta-analysis
of AD reported to date, and individual genotype data from a large subset of IGAP to estimate
the unconfounded association between each risk factor and AD risk. S1 Fig illustrates the
study design.
SNPs Associated with Alzheimer Disease Risk Factors
We identified SNPs that had genome-wide significant (p< 5 × 10−8) associations with each
risk factor using the largest published genome-wide meta-analysis available in individuals of
European ancestry. We identified 49 SNPs associated with T2D [13], 36 with fasting glucose
[14], and ten with insulin resistance [14,15]. We identified 32 SNPs associated with BMI [16]
and 25 associated with systolic blood pressure (SBP) [17]. Given the overlap of SNPs associated
with systolic, diastolic, mean arterial, and pulse pressures, we focused on SBP, which had the
largest number of associated SNPs [17,18]. We identified 74 SNPs associated with total choles-
terol, 71 with high-density lipoprotein (HDL)–cholesterol, 58 with low-density lipoprotein
(LDL)–cholesterol, and 40 with triglycerides [19]. We identified one SNP associated with
smoking initiation (rs6265 in BDNF; r2 = 0.74 with the BDNF BMI-associated variant), and
three associated with smoking quantity in smokers [20]. We identified two SNPs associated
with the probability of completing university and one associated with the number of years
of education [21]. We show the SNPs and their associations with their relative traits in S1
Table. Where lead SNPs were not available, we selected a suitable proxy (r2> 0.8; except for
rs4420638, where the best available proxy was rs6857 [r2 = 0.46]), as detailed in S1 Table. With-
in each trait, no SNPs were in linkage disequilibrium (LD) (r2< 0.01). No SNPs have been re-
ported to be associated with physical activity levels or depression at p< 5 × 10−8.
Alzheimer Disease Genetic Data
IGAP is a large two-stage study based upon genome-wide association studies (GWASs) of AD
in individuals of European ancestry [12]. In stage 1, IGAP used genotyped and imputed data
on 7,055,881 SNPs to meta-analyze four previously published GWAS datasets consisting of
17,008 AD cases and 37,154 controls (full details in S1 Text). Further details on the original ge-
netic discovery analyses, including information regarding recruitment and diagnostic assess-
ment as well as analytical approaches to adjust for population structure, are provided in S1
Text or described in detail elsewhere [12]. We extracted individual SNP associations with AD
from IGAP’s stage 1 results. Three SNPs (rs850303 for SBP; rs3177928 for total and LDL-
cholesterol; rs645040 for triglycerides) were not available (S1 Table), so were excluded from
analyses.
Mendelian Randomization Analyses
We used estimated SNP—risk factor and SNP—AD associations to calculate estimates of each
risk factor—AD association using an inverse-variance weighted combination of estimates from
each SNP [22]. For continuous exposures (BMI, fasting glucose, insulin resistance, lipids, and
SBP), we scaled MR estimates per standard deviation (SD) difference of the risk factor. Effect
sizes on log-fasting insulin were used as weights for the insulin-resistance-associated variants.
SDs were estimated from up to 10,445 (Nmin = 9,963) middle-aged adults from the UK
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AG019757; University of Washington, P50
AG005136; Vanderbilt University, R01 AG019085;
and Washington University, P50 AG005681, P01
AG03991. The Kathleen Price Bryan Brain Bank at
Duke University Medical Center is funded by NINDS
grant # NS39764, NIMH MH60451 and by Glaxo
Smith Kline. Genotyping of the TGEN2 cohort was
supported by Kronos Science. The TGen series was
also funded by NIA grant AG041232 to AJM and
MJH, The Banner Alzheimer’s Foundation, The
Johnnie B. Byrd Sr. Alzheimer’s Institute, the Medical
Research Council, and the state of Arizona and also
includes samples from the following sites: Newcastle
Brain Tissue Resource (funding via the Medical
Research Council, local NHS trusts and Newcastle
University), MRC London Brain Bank for
Neurodegenerative Diseases (funding via the Medical
Research Council),South West Dementia Brain Bank
(funding via numerous sources including the Higher
Education Funding Council for England (HEFCE),
Alzheimer’s Research Trust (ART), BRACE as well
as North Bristol NHS Trust Research and Innovation
Department and DeNDRoN), The Netherlands Brain
Bank (funding via numerous sources including
Stichting MS Research, Brain Net Europe,
Hersenstichting Nederland Breinbrekend Werk,
International Parkinson Fonds, Internationale Stiching
Alzheimer Onderzoek), Institut de Neuropatologia,
Servei Anatomia Patologica, Universitat de
Barcelona. Funding for ADNI is through the Northern
population-based Fenland study [23]. Causal estimates are thus presented per genetically pre-
dicted SD, and a log-linear association with odds of AD is implicit across the range of interme-
diate risk factor values. We scaled smoking quantity per ten cigarettes per day and scaled
educational attainment per year of education. For binary exposures (T2D, smoking initiation,
completing university), MR estimates are odds ratios (ORs) per genetically predicted unit dif-
ference in log-odds of having the relevant exposure. Overall, we included 302 non-overlapping
SNPs. To minimize the possibility of pleiotropic associations influencing results, we performed
sensitivity analyses excluding SNPs with a more significant association with AD than expected
by chance (p< 0.05/302 = 0.00017), which excluded only four variants in total (S1 Table). Fur-
thermore, we investigated the association of each variant with the risk factor relative to the
magnitude of association with AD risk to further identify variants that appeared to be outliers
and were candidates to be pleiotropic. As a further sensitivity analysis, for risk factors that
showed evidence of a causal association with AD (p< 3.8 × 10−3), we also performed a “leave
one out” analysis to further investigate the possibility that the causal association was driven by
a single SNP.
We also performed MR analyses of risk factors that showed evidence of a causal association
with AD (p< 3.8 × 10−3) using individual-level SNP data from studies in the Alzheimer’s Dis-
ease Genetics Consortium (ADGC) (cases = 10,079; controls = 9,613) [24] and the Genetic and
Environmental Risk in AD (GERAD1) Consortium (cases = 3,146; controls = 1,224) [25],
which account for 51% of the IGAP effective sample size (see S1 Text for a description of the
ADGC and GERAD1 samples). We performed logistic regression analyses of the SNP-pre-
dicted AD association adjusting for study site, population substructure, age, and sex, again
scaled per 1-SD difference in risk factor.
We created unweighted genetic scores based on the number of risk alleles for each SNP—
risk factor association and investigated the association of these scores with a range of traits in
up to 16,554 individuals from the EPIC-InterAct study [26] to check the assumption that the
SNPs used in the MR analyses are not associated with potential confounders of exposure—AD
associations. We standardized outcomes and included scores in linear regression models ad-
justed for age, sex, recruitment center, and subcohort status. We natural-log-transformed tri-
glyceride levels before standardization. We investigated the association of the SBP-associated
variants with both SBP and diastolic blood pressure (DBP). We did not adjust observed blood
pressure values for antihypertensive usage. We used logistic regression to determine associa-
tions with the probability of being physically active, being a smoker, or taking antihypertensive
medications, and included covariates as above. The distribution of the SBP risk score in the
EPIC-InterAct study [26] is shown in S2 Fig.
Results
Table 1 shows the estimated associations of each genetically predicted risk factor with AD from
MR analysis using a large-scale international investigation of the genetic basis of AD risk in
17,008 individuals with AD and 37,154 controls. We observed evidence for a causal association
between genetically predicted SBP and AD risk. A genetically predicted 1-SD (15.4 mm
Hg) higher SBP was associated with lower risk of AD (OR [95% CI]: 0.75 [0.62–0.91]; p =
3.4 × 10−3). We examined each of the SBP SNPs to investigate if particular SNPs were driving
the association with AD, but observed no obvious outliers (S3 Fig). Furthermore, when we per-
formed all 24 permutations of the “leave one out” analysis, all SNP sets showed consistent evi-
dence of causality (OR per SD of SBP [95% CI] ranged from 0.72 [0.59–0.87] to 0.78 [0.64–
0.95]). Individual SNP associations with AD are shown in S1 Table. We also performed
analyses on a subset of the overall sample using individual-level SNP data from ADGC and
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GERAD1, which showed results similar to those observed using the inverse-variance weighted
approach (OR [95% CI]: 0.69 [0.55–0.85]; p = 2.0 × 10−3; Fig 1). We saw no evidence of hetero-
geneity between individual studies (p = 0.33).
In the EPIC-InterAct study, the unweighted SBP genetic score was strongly associated
with SBP and DBP overall (Fig 2) and in all age groups (Fig 3) (p< 0.015 for SBP; p< 0.002
for DBP). We did not observe associations of the SBP score with other potentially confound-
ing variables in the EPIC-InterAct study (Fig 2). The unweighted SBP genetic score was asso-
ciated with a higher probability of taking antihypertensive medication (OR [95% CI]: 1.05
[1.03–1.08]; p = 6.7 × 10−8) but not with the probability of being physically active or being a
smoker (Fig 4). Forty-nine percent of the individuals in the highest quartile of the unweighted
SBP genetic score reported taking antihypertensive medication compared to 39% in the
lowest quartile.
We found strong associations between genetically predicted total, LDL-, and HDL-choles-
terol and AD (Table 1). Each of these SNP sets included rs6857 near APOE, which is strongly
associated with AD risk (OR: 3.2; p = 2.5 × 10−575) [12] (S4 and S5 Figs) and which was a very
clear outlier when we compared effect sizes on lipids against effect sizes on AD (S6–S11 Figs).
Two of these SNP sets also included rs1883025 from ABCA1, which was associated with AD at
a significance level beyond that expected by chance (OR: 1.07; p = 1.0 × 10−4) [12] and which is
in a gene previously implicated in association with AD [27]. After sensitivity analyses excluding
these potentially pleiotropic SNPs, we saw no evidence for causal associations between lipid
fractions and AD risk (Table 1).
We found no evidence to support causal associations between BMI and AD (OR per SD of
BMI [95% CI]: 0.99 [0.80–1.19]; p = 0.78), fasting glucose (OR [95% CI]:1.12 [0.97–1.30]; p =
0.11), insulin resistance (OR [95% CI]: 1.32 [0.89–1.97]; p = 0.17), or T2D (OR [95% CI]: 1.01
[0.96–1.07]; p = 0.57) (Table 1). S4 Fig shows the associations with AD of the SNPs included in
all genetic analyses compared to those expected by chance. Other than rs6857 near APOE, the
most significant associations with AD were observed for rs11039149 (p = 3.7 × 10−6) in the
fasting glucose SNPs and rs3817334 (p = 9.3 × 10−5) in the BMI SNPs (see S1 Table and S5
Fig). These SNPs are both in LD (r2 = 0.58 and r2 = 0.33, respectively) with a genome-wide
significant association signal for AD in CELF1 [12]. After excluding these variants from their
respective SNP sets, BMI results were unchanged (Table 1). However, for fasting glucose, fol-
lowing the removal of rs11039149 nearMADD, there was a suggestion of an association be-
tween higher glucose and higher AD risk (OR [95% CI]: 1.19 [1.03–1.37]; p = 0.02).
We found no evidence to support causal associations between smoking initiation and AD
(OR [95% CI]: 0.70 [0.37–1.33]; p = 0.28). We did find an association between genetically pre-
dicted higher smoking quantity and lower AD (OR per ten cigarettes/day [95% CI]: 0.67 [0.51–
0.89]; p = 6.5 × 10−3). We did not have smoking behavior data for IGAP to obtain estimates for
the association with AD among smokers and non-smokers. The SNP with the strongest associ-
ation with smoking quantity [20] was nominally associated with AD risk (rs1051730: OR of
AD per smoking-quantity-raising allele [95% CI]: 0.96 [0.93–0.99]; p = 0.01), while the others
were not (S12 Fig). We saw no association between AD risk and either university completion
(OR [95% CI]: 0.95 [0.67–1.34]; p = 0.75) or years of education (OR [95% CI]: 0.71 [0.48–
1.06]; p = 0.10) (Table 1).
Discussion
The potential of risk factor modifications to impact upon AD incidence depends entirely
on causal links between the risk factors and AD. Using genetic variants associated with risk fac-
tors for AD in a very large consortium of well-characterized research participants, we found
Associations between Modifiable Risk Factors and Alzheimer's Disease
PLOSMedicine | DOI:10.1371/journal.pmed.1001841 June 16, 2015 5 / 16
German Research Center for Environmental Health;
BMBF; German National Genome Research Network
and the Munich Center of Health Sciences. The
Heinz Nixdorf Recall cohort was funded by the Heinz
Nixdorf Foundation (Dr. jur. G.Schmidt, Chairman)
and BMBF. Coriell Cell Repositories is supported by
NINDS and the Intramural Research Program of the
National Institute on Aging. We acknowledge use of
genotype data from the 1958 Birth Cohort collection,
funded by the MRC and the Wellcome Trust which
was genotyped by the Wellcome Trust Case Control
Consortium and the Type-1 Diabetes Genetics
Consortium, sponsored by the National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institute of Allergy and Infectious Diseases,
National Human Genome Research Institute,
National Institute of Child Health and Human
Development and Juvenile Diabetes Research
Foundation International. The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: SDØ has received speaking
fees, consultant honoraria and travel support from
Janssen-Cilag until April 2011. Furthermore, he has
received travel support at one occasion in 2010 from
Bristol-Myers Squibb. EBL reports grants from
National Institute on Aging during the conduct of the
study, and personal fees from UpToDate outside the
submitted work. All other authors have nothing to
disclose.
Abbreviations: AD, Alzheimer disease; ADGC,
Alzheimer’s Disease Genetics Consortium; BMI, body
mass index; DBP, diastolic blood pressure; GERAD1,
Genetic and Environmental Risk in AD; GWAS,
genome-wide association study; HDL, high-
density lipoprotein; IGAP, International Genomics of
Alzheimer’s Project; LD, linkage disequilibrium; LDL,
low-density lipoprotein; MR,
Mendelian randomization; OR, odds ratio; SD,
standard deviation; SNP, single
nucleotide polymorphism; SBP, systolic
blood pressure; T2D, type 2 diabetes.
evidence for an association between genetically inherited higher levels of blood pressure and
lower AD risk.
Hypertension has been implicated as a risk factor for AD [5]. However, uncertainties remain
over the nature of the association, perhaps complicated by misclassification of AD with other
forms of dementia, or the age of study participants [28]. While previous studies have suggested
that high blood pressure in midlife is associated with higher AD risk [29,30], other studies have
indicated that high blood pressure in late life may be protective against AD [31,32]. We found
that genetically inherited higher SBP levels are associated with lower risk of AD (Table 1). Pre-
vious studies have suggested that hypotension may indeed be a risk factor for AD, particularly
in the elderly [33], potentially via resultant cerebral hypoperfusion [34]. The unweighted SBP
gene score was associated with higher SBP levels across the adult lifespan (Fig 3). It should be
noted that the SNPs associated with SBP overlap extensively with those associated with DBP
[17] as well as with pulse pressure [18], so we were unable to distinguish between individual
components of blood pressure. A recent meta-analysis of prospective studies suggested that a
10-mm Hg higher SBP was associated with a protective relative risk of 0.95 (95% CI: 0.91–1.00)
for AD [28]. Scaling our results to a genetically predicted 10-mmHg difference in SBP would
result in an OR of 0.83 (95% CI: 0.73–0.94) for AD. Clearly, given that blood pressure is a
major risk factor for cardiovascular disease [35], one would not advocate raising blood pressure
as a preventive strategy, yet these findings offer intriguing etiological insight.
We also found that genetically predicted higher SBP was associated with a higher probability
of being on antihypertensive medication (Fig 4). There is considerable interest in the role of an-
tihypertensives in dementia, and while findings are equivocal [36], recent studies have sug-
gested a possible protective effect of antihypertensive therapy on AD risk [37], potentially with
heterogeneity of effect by therapeutic class [38], suggesting that any effect on AD risk may not
be entirely attributable to the lowering of blood pressure, but potentially to other mechanisms.
The unweighted SBP gene score was strongly associated with observed SBP in the EPIC-Inter-
Act study, ignoring any SBP-lowering effects of antihypertensive medications. Thus, if antihy-
pertensive medications are indeed protective and confound the association between genetically
Table 1. Estimated associations of each genetically predicted risk factor with Alzheimer disease.
Trait Scaling of OR Number of SNPs Overall Results Sensitivity Analyses*
OR (95% CI) p-Value OR (95% CI) p-Value
BMI 1 SD (4.81 kg/m2) 32 0.99 (0.80−1.19) 0.779 1.00 (0.82−1.22) 0.97
T2D 1 unit higher log-odds 49 1.02 (0.97−1.07) 0.535
Fasting glucose 1 SD (0.65 mmol/l) 36 1.12 (0.97−1.30) 0.112 1.19 (1.03−1.37) 0.02
Insulin resistance 1 SD log-FI (0.60 log-pmol/l) 10 1.32 (0.88−1.98) 0.177
SBP 1 SD (15.4 mm Hg) 24 0.75 (0.62−0.91) 3.4 × 10−3
Total cholesterol 1 SD (1.03 mmol/l) 73 1.94 (1.79−2.10) 3.1 × 10−56 1.04 (0.95−1.13) 0.84
HDL-cholesterol 1 SD (0.41 mmol/l) 71 0.75 (0.69−0.82) 1.0 × 10−11 1.01 (0.93−1.09) 0.87
LDL-cholesterol 1 SD (0.91 mmol/l) 57 2.31 (2.12−2.50) 3.0 × 10−87 1.07 (0.98−1.17) 0.14
Triglycerides 1 SD (0.83 mmol/l) 39 0.96 (0.87−1.07) 0.482
Smoking initiation 1 unit higher log-odds 1 0.70 (0.37−1.33) 0.278
Smoking quantity 10 cigarettes/day 3 0.67 (0.51−0.89) 6.5 × 10−3
Completing university 1 unit higher log-odds 2 0.95 (0.67−1.34) 0.752
Length of education 1 year of education 1 0.71 (0.48−1.06) 0.097
*Sensitivity analyses exclude SNPs where p < 0.00017 (0.05/302 unique SNPs) for AD.
log-FI, log-fasting insulin.
doi:10.1371/journal.pmed.1001841.t001
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predicted SBP and AD, their effect on AD risk is likely to be independent of their effect on SBP,
as the SBP-associated variants have a strong association with SBP regardless of the higher prev-
alence of treatment with antihypertensive medication. While the null association between ge-
netically predicted lipid levels and AD risk reflects the equivocal findings from trials of statins
and cognitive decline [39], our results suggest the imperative need for further investigation of
the possibility that antihypertensive medications may reduce AD risk independently of their ef-
fects on blood pressure. Future MR analyses stratified by antihypertensive treatments would be
desirable to more precisely estimate the magnitude of the causal effect of higher BP on AD risk,
Fig 1. Mendelian randomization estimates of the association of systolic blood pressure with AD in individual ADGC studies and overall in ADGC,
GERAD1, and IGAP. This figure shows MR estimates for the association of SBP-associated variants with AD in each of the participant studies in ADGC [24]
and in GERAD1 [25] using individual SNP-level data compared to that observed in IGAP [12] using summary-level data. See S1 Text (supplemental results)
for individual study name abbreviations.
doi:10.1371/journal.pmed.1001841.g001
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Fig 2. Associations of the systolic blood pressure genetic score with quantitative traits in the EPIC-InterAct study. This figure shows the
investigation of pleiotropic associations of genetic score for SBP with quantitative traits in the EPIC-InterAct study [26]. Effect sizes are expressed in SDs per
SBP-raising allele. Analyses were adjusted for age, sex, center of recruitment, and subcohort status.
doi:10.1371/journal.pmed.1001841.g002
Fig 3. Association of the systolic blood pressure genetic score with systolic blood pressure by age
stratum in the EPIC-InterAct subcohort. This figure shows the association between the genetic score for
SBP and SBP in the EPIC-InterAct study by age stratum [26]. Analyses were adjusted for sex, center of
recruitment, and subcohort status.
doi:10.1371/journal.pmed.1001841.g003
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but will be difficult to carry out using existing data due to the time-varying nature of antihyper-
tensive treatments across the life course, and the non-availability of data on lifetime medication
usage in most studies.
We also observed an association between AD and smoking quantity (Table 1). Early reports
implicated smoking as protective for AD [40], potentially via a neuroprotective effect of nico-
tine [41]. However, this association may be due to differential survival bias [42], and a recent
meta-analysis of prospective studies implicates smoking as a risk factor for AD, showing cur-
rent smokers as being at higher risk of AD than never smokers [8]. One smoking-quantity-
related SNP was associated with AD (p = 0.01). This SNP is in the gene CHRNA3 from the nic-
otinic receptor gene cluster CHRNA5-CHRNA3-CHRNB4. Given the putative actions of nico-
tine, variants in this locus may confer neuroprotective effects by influencing nicotinic receptor
function [41,43]. Thus, altered nicotinic receptor function may underlie the MR association be-
tween smoking quantity and AD risk. The ideal study would perform MR analyses stratified by
smoking status [44], particularly if sensitivity analyses could exclude variants in nicotinic re-
ceptor genes. Such analyses would address the causality of smoking as a risk factor, and offer
valuable insight into nicotine’s role in the etiology of AD [41,43]. Since smoking is a major
cause of global disease burden [45], increasing knowledge of the role of nicotine in the etiology
of AD may prove to be the more actionable insight.
Our findings for total, LDL-, and HDL-cholesterol are not consistent with a causal effect of
major lipid fractions on AD risk, as previously suggested in a smaller study [46]. Rather, the
well-established association of APOE haplotypes with AD risk [47] implicates APOE itself as a
key causal factor in the etiology of AD. Indeed a recent GWAS of plasma APOE levels identi-
fied only genetic variants in APOE, and not those in other lipid loci, as being associated with
Fig 4. Associations of the systolic blood pressure genetic score with binary outcomes in the EPIC-InterAct study. This figure shows the investigation
of pleiotropic associations of the genetic score for SBP with binary outcomes in the EPIC-InterAct study [26]. The OR per SBP-raising allele is shown.
doi:10.1371/journal.pmed.1001841.g004
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APOE levels at genome-wide significance [48]. When we compared the effect sizes for the ef-
fects of SNPs on major lipids relative to the magnitude of their association with AD, the APOE
variant was a very clear outlier (S6–S11 Figs).
We did not find evidence consistent with a causal role for the other potentially modifiable
risk factors we evaluated (Table 1). In our sensitivity analysis that excluded the potentially
pleiotropic variant nearMADD, genetically predicted higher fasting glucose was nominally as-
sociated with higher AD risk. While these results are consistent with the notion that higher
blood glucose may be causally related to AD risk [4], the borderline significance warrants a
cautious interpretation.
A limitation of the MR approach is the limited strength of the SNPs to explain variation in
the intermediate traits, restricting statistical power. This is particularly true when findings are
null, where narrow confidence intervals are important to aid robust inference. For example,
while we saw no evidence to support causal roles for BMI, fasting glucose, or insulin resistance
in AD (all p> 0.1), confidence intervals allow for an almost 20% higher AD risk per 1-SD dif-
ference in BMI, a 30% higher AD risk per 1-SD difference in fasting glucose, and an almost
100% higher AD risk per 1-SD difference in log-fasting insulin (Table 1). Thus, improving the
intermediate trait variance explained by the instrumental variables by further genetic discovery
efforts will improve the precision of MR analyses. Likewise, ever larger AD GWASs will further
narrow confidence intervals around MR estimates. The association of genetically predicted
blood pressure with AD risk remained after Bonferroni correction for the 13 individual SNP
sets we tested (0.05/13 = 3.8 × 10−3), although the association of the smoking-associated vari-
ants did not. However, we consider this a conservative correction, given the correlation be-
tween the intermediate risk factors. We cannot exclude the possibility that the protective
associations of blood pressure with AD arise as a result of differential survival bias, but the con-
sistency of the observations across both prospective and cross-sectional studies of AD makes
this less likely (Fig 1), as does the absence of similar MR associations for other major vascular
risk factors (Table 1).
The main data source for this study is the summary statistics from IGAP, the largest ge-
nome-wide meta-analysis of AD reported to date [12]. Since all participants in IGAP are of Eu-
ropean ancestry, the results of this study are not necessarily valid for other ethnic groups.
In conclusion, we found associations between genetically predicted higher SBP and lower
AD risk. This finding is contrary to the notion that societal interventions to lower blood pres-
sure will reduce the incidence of AD. However, since there is a strong association between
higher SBP gene scores and exposure to antihypertensive treatments, there is a need to evaluate
the possible protective role of some of these substances against AD, independent of their effects
on blood pressure.
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S1 Fig. Illustration of the study design.
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S2 Fig. Distribution of the systolic blood pressure genetic risk score in the EPIC-InterAct
study. n = 16,691.
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S3 Fig. Estimated associations of SNPs with AD (ln-ORs and 95% CIs) from IGAP [12]
against their estimated associations with SBP from [17].
(TIF)
S4 Fig. QQ plot of SNP associations with Alzheimer disease. SNPs from all scores (Nunique =
302) were LD-pruned and duplicates were removed to leave the 269 variants shown here. The
SNP near APOE (rs6857) had a p-value of 2.5 × 10−575, which was truncated to 10−30 for display
on the figure.
(TIF)
S5 Fig. QQ plot of SNP associations with Alzheimer disease excluding the APOE allele.
SNPs from all scores (Nunique = 302) were LD-pruned and duplicates were removed to leave
269 variants. For the present plot, the SNP near APOE (rs6857, p = 2.5 × 10−575) was excluded
(see S4 Fig).
(TIF)
S6 Fig. Estimated associations of SNPs with AD (ln-ORs and 95% CIs) from IGAP [12]
against their estimated associations with total cholesterol from [19] including the APOE
allele.
(TIF)
S7 Fig. Estimated associations of SNPs with AD (ln-ORs and 95% CIs) from IGAP [12]
against their estimated associations with total cholesterol from [19] excluding the APOE
allele.
(TIF)
S8 Fig. Estimated associations of SNPs with AD (ln-ORs and 95% CIs) from IGAP [12]
against their estimated associations with HDL-cholesterol from [19] including the APOE
allele.
(TIF)
S9 Fig. Estimated associations of SNPs with AD (ln-ORs and 95% CIs) from IGAP [12]
against their estimated associations with HDL-cholesterol from [19] excluding the APOE
allele.
(TIF)
S10 Fig. Estimated associations of SNPs with AD (ln-ORs and 95% CIs) from IGAP [12]
against their estimated associations with LDL-cholesterol from [19] including the APOE
allele.
(TIF)
S11 Fig. Estimated associations of SNPs with AD (ln-ORs and 95% CIs) from IGAP [12]
against their estimated associations with LDL-cholesterol from [19] excluding the APOE
allele.
(TIF)
S12 Fig. Estimated associations of SNPs with AD (ln-ORs and 95% CIs) from IGAP [12]
against their estimated associations with smoking quantity derived from the Tobacco and
Genetics Consortium GWAS [20]. Note that the effect sizes for the effects of SNPs on smok-
ing quantity were estimated in current smokers only, while the associations with AD are not
stratified by smoking status.
(TIF)
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European 1000 Genomes samples.
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Editors' Summary
Background
Worldwide, about 44 million people have dementia, a group of brain degeneration disor-
ders characterized by an irreversible decline in memory, communication, and other “cog-
nitive” functions. Dementia mainly affects older people, and because people are living
longer, experts estimate that more than 135 million people will have dementia by 2050.
The most common form of dementia, which accounts for 60%–70% of cases, is Alzheimer
disease (AD). The earliest sign of AD is often increasing forgetfulness. As the disease pro-
gresses, affected individuals gradually lose the ability to look after themselves, they may be-
come anxious or aggressive, and they may have difficulty recognizing friends and relatives.
People with late stage disease may lose control of their bladder and of other physical func-
tions. At present, there is no cure for AD, although some of its symptoms can be managed
with drugs. Most people with AD are initially cared for at home by relatives and other
caregivers, but many affected individuals end their days in a care home or specialist
nursing home.
WhyWas This Study Done?
Researchers are interested in identifying risk factors for AD, particularly modifiable risk
factors, because if such risk factors exist, it might be possible to limit the predicted increase
in future AD cases. Epidemiological studies (investigations that examine patterns of dis-
ease in populations) have identified several potential risk factors for AD, including hyper-
tension (high blood pressure), obesity, smoking, and dyslipidemia (changes in how the
body handles fats). However, epidemiological studies cannot prove that a specific risk fac-
tor causes AD. For example, people with hypertension might share another characteristic
that causes both hypertension and AD (confounding) or AD might cause hypertension
(reverse causation). Information on causality is needed to decide which risk factors to tar-
get to help prevent AD. Here, the researchers use “Mendelian randomization” to examine
whether differences in several epidemiologically identified risk factors for AD have a caus-
al impact on AD risk. In Mendelian randomization, causal associations are inferred from
the effects of genetic variants (which predict levels of modifiable risk factors) on the out-
come of interest. Because gene variants are inherited randomly, they are not prone to con-
founding and are free from reverse causation. So, if hypertension actually causes AD,
genetic variants that affect hypertension should be associated with an altered risk of AD.
What Did the Researchers Do and Find?
The researchers identified causal associations between potentially modifiable risk factors
and AD risk by analyzing the occurrence of single nucleotide polymorphisms (SNPs, a
type of gene variant) known to predict levels of each risk factor, in genetic data from
17,008 individuals with AD and 37,154 cognitively normal elderly controls collected by
the International Genomics of Alzheimer’s Project. They report that genetically predicted
higher systolic blood pressure (SBP; the pressure exerted on the inside of large blood ves-
sels when the heart is pumping out blood) was associated with lower AD risk (and with a
higher probability of taking antihypertensive medication). Predicted smoking quantity
was also associated with lower AD risk, but there was no evidence of causal associations
between any of the other risk factors investigated and AD risk.
Associations between Modifiable Risk Factors and Alzheimer's Disease
PLOSMedicine | DOI:10.1371/journal.pmed.1001841 June 16, 2015 15 / 16
What Do These Findings Mean?
In contrast to some epidemiological studies, these findings suggest that hypertension is as-
sociated with lower AD risk. However, because genetically predicted higher SBP was also
associated with a higher probability of taking antihypertensive medication, it could be that
exposure to such drugs, rather than having hypertension, reduces AD risk. Like all Mende-
lian randomization studies, the reliability of these findings depends on the validity of sev-
eral assumptions made by the researchers and on the ability of the SNPs used in the
analyses to explain variations in exposure to the various risk factors. Moreover, because all
the participants in the International Genomics of Alzheimer’s Project are of European an-
cestry, these findings may not be valid for other ethnic groups. Given that hypertension is
a risk factor for cardiovascular disease, the researchers do not advocate raising blood pres-
sure as a measure to prevent AD (neither do they advocate that people smoke more ciga-
rettes to lower AD risk). Rather, given the strong association between higher SBP gene
scores and the probability of exposure to antihypertensive treatment, they suggest that the
possibility that antihypertensive drugs might reduce AD risk independently of their effects
on blood pressure should be investigated as a priority.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001841.
• The UK National Health Service Choices website provides information (including per-
sonal stories) about Alzheimer disease
• The UK not-for-profit organization Alzheimer’s Society provides information for pa-
tients and carers about dementia, including personal experiences of living with
Alzheimer disease
• The US not-for-profit organization Alzheimer’s Association also provides information
for patients and carers about dementia and personal stories about dementia
• Alzheimer’s Disease International is the federation of Alzheimer disease associations
around the world; it provides links to individual Alzheimer associations, information
about dementia, and links to world Alzheimer reports
• MedlinePlus provides links to additional resources about Alzheimer disease (in English
and Spanish)
• Wikipedia has a page on Mendelian randomization (note: Wikipedia is a free online en-
cyclopedia that anyone can edit; available in several languages)
• A PLOS Medicine Research Article by Proitsi et al. describes a Mendelian randomization
study that looked for a causal association between dyslipidemia and Alzheimer disease
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